The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer

Angiogenesis, a hallmark of cancer, plays a fundamental role in colorectal cancer (CRC). Anti-angiogenic drugs and chemotherapy represent a standard of care for treating metastatic disease. Immune checkpoint inhibitors (ICIs) have changed the therapeutic algorithm of many solid tumors. However, the...

Full description

Saved in:
Bibliographic Details
Published in:Life (Basel, Switzerland) Switzerland), 2022-10, Vol.12 (10), p.1552
Main Authors: Maiorano, Brigida Anna, Parisi, Alessandro, Maiello, Evaristo, Ciardiello, Davide
Format: Article
Language:English
Subjects:
Algorithms
Angiogenesis
anti-angiogenics
Antiangiogenic agents
Antiangiogenics
Anticancer properties
Biomarkers
Blood vessels
Cancer
Cancer therapies
Cell adhesion & migration
Chemokines
Chemotherapy
Colorectal cancer
Colorectal carcinoma
CRC
Cytokines
Dendritic cells
Deoxyribonucleic acid
DNA
Effectiveness
FDA approval
Hypoxia
ICIs
Immune checkpoint inhibitors
Immune system
Immunomodulation
Immunosuppressive agents
Immunotherapy
Inhibitors
Ligands
Malignancy
Metastases
Metastasis
Microsatellite instability
Microsatellites
Mutation
Patients
Proteins
Response rates
Review
Solid tumors
Tumors
Vascular endothelial growth factor
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Angiogenesis, a hallmark of cancer, plays a fundamental role in colorectal cancer (CRC). Anti-angiogenic drugs and chemotherapy represent a standard of care for treating metastatic disease. Immune checkpoint inhibitors (ICIs) have changed the therapeutic algorithm of many solid tumors. However, the efficacy of ICIs is limited to mCRC patients carrying microsatellite instability (MSI-H), which represent approximately 3–5% of mCRC. Emerging evidence suggests that anti-angiogenic drugs could exhibit immunomodulatory properties. Thus, there is a strong rationale for combining anti-angiogenics and ICIs to improve efficacy in the metastatic setting. Our review summarizes the pre-clinical and clinical evidence regarding the combination of anti-angiogenics and ICIs in mCRC to deepen the possible application in daily clinical practice.
ISSN:2075-1729
2075-1729
DOI:10.3390/life12101552